Clinical impact of a pharmacist-led medication review with follow up for aged polypharmacy patients: A cluster randomized controlled trial

Raquel Varas-Doval, Miguel A Gastelurrutia, Shalom I Benrimoj, Victoria García-Cárdenas, Loreto Sáez-Benito, Fernando Martinez-Martínez, Raquel Varas-Doval, Miguel A Gastelurrutia, Shalom I Benrimoj, Victoria García-Cárdenas, Loreto Sáez-Benito, Fernando Martinez-Martínez

Abstract

Background: Medication review with follow-up (MRF) is a service where community pharmacists undertake a medication review with monthly follow-up to provide continuing care. The ConSIGUE Program assessed the impact and implementation of MRF for aged polypharmacy patients in Spanish Community Pharmacies. The present paper reports on the clinical impact evaluation phase of ConSIGUE.

Objective: The main objective of the study was to measure the effect of MRF on the primary outcome of the number of uncontrolled health problems. Secondary objectives were to analyze the drug-related problems (DRPs) identified as potential causes of ineffective or unsafe medications and the pharmacists' interventions implemented during MRF provision.

Methods: An open-label multi-centered cluster randomized study with comparison group (CG) was carried out in community pharmacies from 4 provinces in Spain during 6 months. The main inclusion criteria were patients over 64 years old, using 5 or more medicines. The intervention group (IG) received the MRF service (advanced medication review-type 3 MR) whereas patients in the CG received usual care.

Results: 178 pharmacies recruited 1403 patients (IG= 688 patients; CG= 715 patients). During the 6 months of the study 72 patients were lost to follow up. The adjusted multi-level random effects models showed a significant reduction in the number of uncontrolled health problems over the periods in the IG (-0.72, 95% CI: -0.80, -0.65) and no change in the CG (-0.03, 95% CI: -0.10, 0.04). Main DRPs identified as potential causes of failures of uncontrolled health problems' treatment were undertreated condition (559 DRPs; 35.81%), lack of treatment adherence (261 DRP; 16.67%) and risk of adverse effects (207 DRPs; 13.53%). Interventions performed by pharmacist to solve DRP mainly included the addition (246 interventions; 14.67%) and change (330 interventions; 19.68%) of a medicine and educational interventions on medicine adherence (231 interventions; 13.78%) and non-pharmacological interventions (369 interventions; 22.01%).

Conclusions: This study provides evidence of the impact of community pharmacist on clinical outcomes for aged patients. It suggests that the provision of an MRF in collaboration with general medical practitioners and patients contributes to the improvement of aged polypharmacy patients' health status and reduces their problems related with the use of medicines.

Keywords: Community Pharmacy Services; Medication Therapy Management; Pharmacies; Pharmacists; Polypharmacy; Randomized Controlled Trials as Topic; Spain; Treatment Adherence and Compliance.

Conflict of interest statement

CONFLICT OF INTEREST The authors declare that there are no competing interests.

Copyright: © Pharmacy Practice and the Authors.

Figures

Figure 1. Flow diagram of patients
Figure 1. Flow diagram of patients
IG: intervention group; CG: comparison group
Figure 2. Type of baseline uncontrolled health…
Figure 2. Type of baseline uncontrolled health problems in the IG and CG

References

    1. World Population Ageing 1950-2050 [Internet] New York: United Nations; [accessed Feb 13 2014]. Available at:
    1. Turner G, Clegg A. British Geriatrics Society;Age UK;Royal College of General Practioners. Best practice guidelines for the management of frailty:a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing. 2014;43(6):744–747. doi: 10.1093/ageing/afu138.
    1. Sorensen L, Stokes JA, Purdie DM, Woodward M, Roberts MS. Medication management at home:medication-related risk factors associated with poor health outcomes. Age Ageing. 2005;34(6):626–632. doi: 10.1093/ageing/afi202.
    1. Aspinall S, Sevick MA, Donohue J, Maher R, Hanlon JT. Medication errors in older adults:a review of recent publications. Am J Geriatr Pharmacother. 2007;5(1):75–84. doi: 10.1016/j.amjopharm.2007.03.009.
    1. ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14(5):488–498. doi: 10.1097/01.mjt.0000183719.84390.4d.
    1. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269–2276. doi: 10.1001/archinte.162.20.2269.
    1. Wiedenmayer K, Summers RS, Mackie CA, Gous AG, Everard M. Developing Pharmacy Practice:A Focus on Patient Care. [accessed Aug 17 2020]. Available at: .
    1. Moullin JC, Sabater-Hernández D, Fernandez-Llimos F, Benrimoj SI. Defining professional pharmacy services in community pharmacy. Res Social Adm Pharm. 2013;9(6):989–995. doi: 10.1016/j.sapharm.2013.02.005.
    1. Benrimoj SI, Feletto E, Gastelurrutia MA, Martinez-Martinez F, Faus MJ. A holistic and integrated approach to implementing cognitive pharmaceutical services. Ars Pharm. 2010;51(2):69–87.
    1. Grupo de Expertos de Foro de Atención Farmacéutica. [Consensus document] Madrid: CGCOF; 2008.
    1. Pharmaceutical Care Research Group, University of Granada (Spain). Pharmacotherapy follow-up:The Dader method (3rd revision (2005) Pharm Pract (Granada) 2006;4(1):44–53.
    1. Sáez-Benito L, Fernandez-Llimos F, Feletto E, Gastelurrutia MA, Martinez-Martinez F, Benrimoj SI. Evidence of the clinical effectiveness of cognitive pharmaceutical services for aged patients. Age Ageing. 2013;42(4):442–449. doi: 10.1093/ageing/aft045.
    1. Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, Bell JS. Pharmacist-led medication review in community settings:An overview of systematic reviews. Res Social Adm Pharm. 2017;13(4):661–685. doi: 10.1016/j.sapharm.2016.08.005.
    1. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions:new guidance [Internet] London: Medical Research Council; [accessed Aug 17 2020]. Available at:
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG. CONSORT Group. Consort 2010 statement:extension to cluster randomised trials. BMJ. 2012;345:e5661. doi: 10.1136/bmjne5661.
    1. Cosby RH, Howard M, Kaczorowski J, Willan AR, Sellors JW. Randomizing patients by family practice:sample size estimation, intracluster correlation and data analysis. Fam Pract. 2003;20(1):77–82. doi: 10.1093/fampra/20.1.77.
    1. van Breukelen GJ, Candel MJ. Efficiency loss due to varying cluster sizes in cluster randomized trials and how to compensate for it:comment on You et al (2011) Clin Trials. 2012;9(1):125–127. doi: 10.1177/174077451142⇉.
    1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie S. Better reporting of interventions:template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. doi: 10.1136/bmj.g1687.
    1. ComitéInternacional de Clasificación de la WONCA. International Classification of Primary Care second edition. CIAP - 2. Barcelona: Masson; 1999.
    1. Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, Lohr KN. Medication therapy management interventions in outpatient settings:a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76–87. doi: 10.1001/jamainternmed.2014.5841.
    1. Sorensen L, Stokes JA, Purdie DM, Woodward M, Elliott R, Roberts MS. Medication reviews in the community:results of a randomized, controlled effectiveness trial [published correction appears in Br J Clin Pharmacol 2005. 2005 Mar;59(3):376] Br J Clin Pharmacol. 2004;58(6):648–664. doi: 10.1111/j.1365-2125.2004.02220.x.
    1. Yang J, Meng L, Liu Y, Lv L, Sun S, Long R, Shan X, Song J, Qiu F. Drug-related problems among community-dwelling older adults in mainland China. Int J Clin Pharm. 2018;40(2):368–375. doi: 10.1007/s11096-017-0587-3.
    1. Rhalimi M, Rauss A, Housieaux E. Drug-related problems identified during geriatric medication review in the community pharmacy. Int J Clin Pharm. 2018;40(1):109–118. doi: 10.1007/s11096-017-0571-y.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren